Analystreport

LogicBio Therapeutics, Inc. (NASDAQ: LOGC) had its price target lowered by analysts at Chardan Capital from $4.00 to $2.50.

LogicBio Therapeutics, Inc.  (LOGC) 
Last logicbio therapeutics, inc. earnings: 8/13 08:00 am Check Earnings Report